Dr. Reddy’s beats revenue forecasts despite US generic headwinds
Dr. Reddy’s Laboratories (NYSE:RDY) reported fiscal third-quarter revenue that surpassed analyst expectations Wednesday, as explosive growth in emerging markets and a resilient domestic business in India helped offset a steep decline in its North American generic portfolio.









-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)